fda update tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Update I received today. :

Proven GLP-1 therapy with years of clinical research

The published Phase II trial by Teichman et al

It slows gastric emptying, reduces hunger signals, and helps control cravings making it significantly easier to reduce calorie intake without feeling deprived

They can also use it to diagnose prediabetes or diabetes

In this study, a 24-h Holter ECG recording was performed at baseline, after the maximum daily dose for each drug (lixisenatide 20 g, liraglutide 0.9 mg) had been administered for at least 1 week following completion of the up-titration period

And on top of all this, some research suggests that lower estrogen levels may also promote fibrosis (a buildup of thick, stiff, scar-like tissue) within the shoulder joint